Yahoo · Aug 14, 2026
UMH Properties and 4 More Stocks See Action From Activist Investors
Activists also report to the SEC on MBX Biosciences, Core Scientific, Gran Tierra Energy, and Shoulder Innovations.
MB
NASDAQ · MBX
MBX Biosciences, Inc. Common Stock
Healthcare · Biotechnology
$66.33
Down-$0.02 (-0.03%)
Updated Aug 22, 2026, 9:00 AM
SID Score
6.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 954.72M
- P/E ratio
- -12.07
- Dividend yield
- 0.00%
- 52-week range
- $9.63 – $72.64
- Volume
- 466.64K
- Avg. volume
- 1.44M
Price performance
MBX price history
1M range · 21 trading sessions · Daily adjusted prices
MBX closed at $66.33 after 21 trading sessions, up 6.98% for the selected period.
- Last close
- $66.33
- Period change
- +6.98%
- Period low
- $60.06
- Period high
- $70.70
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $67.86 | $67.86 | $65.5908 | $66.33 | 466.64K |
| Aug 20, 2026 | $67.00 | $68.49 | $65.3956 | $66.35 | 422.51K |
| Aug 19, 2026 | $67.53 | $68.76 | $65.25 | $68.40 | 562.35K |
| Aug 18, 2026 | $66.40 | $69.05 | $65.795 | $66.52 | 560.74K |
| Aug 17, 2026 | $68.28 | $69.94 | $67.58 | $68.25 | 461.17K |
| Aug 14, 2026 | $67.00 | $68.84 | $65.01 | $68.57 | 503.14K |
| Aug 13, 2026 | $66.97 | $68.41 | $65.50 | $67.08 | 334.92K |
| Aug 12, 2026 | $66.84 | $67.80 | $66.00 | $66.97 | 331.49K |
| Aug 11, 2026 | $67.46 | $68.49 | $65.11 | $66.01 | 359.76K |
| Aug 10, 2026 | $67.71 | $68.215 | $65.30 | $66.15 | 325.46K |
| Aug 7, 2026 | $69.69 | $70.00 | $65.255 | $67.82 | 545.51K |
| Aug 6, 2026 | $66.19 | $68.86 | $64.50 | $67.11 | 528.71K |
| Aug 5, 2026 | $70.00 | $72.64 | $67.0387 | $67.48 | 487.5K |
| Aug 4, 2026 | $64.78 | $71.12 | $64.74 | $70.70 | 696.04K |
| Aug 3, 2026 | $65.99 | $66.485 | $62.68 | $64.41 | 390.73K |
| Jul 31, 2026 | $67.00 | $69.40 | $64.50 | $65.93 | 566.28K |
| Jul 30, 2026 | $64.84 | $66.66 | $62.985 | $66.46 | 548.13K |
| Jul 29, 2026 | $61.78 | $65.989 | $60.58 | $63.96 | 564.72K |
| Jul 28, 2026 | $61.98 | $62.005 | $58.785 | $60.06 | 625.72K |
| Jul 27, 2026 | $62.24 | $64.775 | $60.40 | $61.30 | 304.27K |
| Jul 24, 2026 | $64.22 | $66.66 | $60.851 | $62.00 | 500.94K |
Latest MBX news
The latest Smart Investors Daily articles mentioning MBX.
Stock researchCompany · Overview
MBX research
Overview
Company profile and research snapshot.
Company profile
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $28.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 21, 2026 | JP Morgan | Overweight | — |
| Aug 10, 2026 | Truist Securities | Buy | — |
| Jul 29, 2026 | Mizuho | Outperform | — |
| May 12, 2026 | Barclays | Overweight | — |
| May 12, 2026 | Citizens | Market Outperform | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 10, 2026
Truist Securities Maintains Buy on MBX Biosciences, Raises Price Target to $88
Truist Securities analyst Srikripa Devarakonda maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $70 to $88.
Yahoo · Aug 6, 2026
MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights
One-year data demonstrated sustained benefit of once-weekly canvuparatide as a potential PTH replacement therapy in chronic hypoparathyroidism; Phase 3 pivotal trial now recruiting Initial Phase 1 data for MBX 4291, a GLP-1/GIP co-agonist prodrug for obesity, support potential for once-monthly dosing; data from 12-week MAD (Part C) on track for Q4 2026 Nomination of development candidate MBX 6180, a GLP-1/GIP/GCG triple agonist prodrug designed for once-monthly dosing, further expands obesity po
Benzinga · Aug 6, 2026
MBX Biosciences Q2 EPS $(0.78) Misses $(0.63) Estimate
MBX Biosciences (NASDAQ:MBX) reported quarterly losses of $(0.78) per share which missed the analyst consensus estimate of $(0.63) by 23.81 percent. This is a 34.48 percent decrease over losses of $(0.58) per share from
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
